RPS6KB1 and renal cell carcinoma: Treatment with XL388 (500 nM) in 786-0 RCC cells led to almost complete inhibition of phosphorylated- (“p-“) mTOR (Ser-2448), p-S6K1 (Thr-389) and p-AKT (Ser-473) (Figure 3A), indicating concurrent inhibition of mTORC1 and mTORC2 [5, 6].